Optimal therapy in genotype 1 patients 3 rd Paris Hepatitis Conference 19-20 January 2009 Stefan...
-
Upload
kara-jaggers -
Category
Documents
-
view
214 -
download
0
Transcript of Optimal therapy in genotype 1 patients 3 rd Paris Hepatitis Conference 19-20 January 2009 Stefan...
Optimal therapy in genotype 1 patients
3rd Paris Hepatitis Conference19-20 January 2009
Stefan Zeuzem, MDJ.W. Goethe University Hospital
Frankfurt, Germany
Standard Treatment
Peginterferon alfa-2a/2b + Ribavirin for treatment of chronic hepatitis C
37
61
46
76
0
20
40
60
80
100
IFN + RBV PEG-IFNalfa-2a +
RBV
33
79
42
82
0
20
40
60
80
100
IFN + RBV PEG-IFNalfa-2b +
RBV
HCV-1
HCV-2,3
Su
sta
ine
d vi
rolo
gic
S
ust
ain
ed
viro
log
ic
resp
ons
e (
%)
resp
ons
e (
%)
Manns et al., Lancet 2001;358:958-965
Fried et al., N Engl J Med 2002; 347:975-982
Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated Interferon
Therapy (IDEAL study)
38 40 41
0
10
20
30
40
50
PEG-IFN alfa-2b(1.0 µg/kg)
PEG-IFN alfa-2b(1.5 µg/kg)
PEG-IFN alfa-2a(180 µg)
EASL 2008 (Late-Breaker Abstract)EASL 2008 (Late-Breaker Abstract)
Sus
tain
ed v
irolo
gic
Sus
tain
ed v
irolo
gic
resp
onse
(%
)re
spon
se (
%)
Virologic response in HCV genotype 1 or 4 infected patients
62,3
75,3
49,547,3
54,8
39,8
20,4
0
10
20
30
40
50
60
70
80
90
100
P<0.0003
P=0.04
Overall PEG IFN alfa-2a PEG IFN alfa-2b
ETR SVR REL
P=0.04
Per
cent
age
15.19.7
Ascione et al., EASL 2008Ascione et al., EASL 2008
62.362.3
47.347.3
75.375.3
54.854.8
20.420.4
49.549.5
39.839.8
Milan Safety Tolerability (MIST) Study
Rumi, Colombo et al, AASLD 2008, A212
p = 0.02 p = 0.02 p = 0.01 p = 0.8
48%
96%
65%
54%
32%
82%
69%66%
0%
20%
40%
60%
80%
100%
Overa
ll SVR
SVR G1/
4
SVR G2
SVR G3
Sus
tain
ed v
irolo
gic
resp
onse
rat
es
PEG alfa-2a
PEG alfa-2b
Retrospective analysis of patients treated with either peginterferon alfa-2a or alfa-2b
(PRACTICE study)
0102030405060708090
100
all GT (N=1672) HCV-1 (N=1108) HCV-2,3 (N=544)
alfa-2a
alfa-2b
Witthöft et al., EASL 2008
Sus
tain
ed v
irolo
gic
rela
pse
rate
(%
)
54.4%
59.1%
43.7%
76.8%
49.6%
78.3%
P=0.05
Optimization of Standard Treatment
*Logit scale5.6 log10 IU/mL ~400 x103 IU/mL
Effect of pre-tx HCV RNA on SVR
Pro
bab
ility
of
SV
R*
Baseline HCV RNA (log10 IU/ml)
3 4 6 75
0.5
0.88
0.98
0.9985.6 log10 IU/mL
0
10
23
0 0 00
17
40
0
10
20
30
40
50
4 8 12
Re
lap
se r
ate
(%
)
Baseline viremia > 800.000 IU/mL
All patients
Baseline viremia ≤ 800.000 IU/mL
Time to HCV RNA < 5.3 IU/mL by TMA in weeks
Relation between the dynamics of virologic response and relapse prediction in patients
receiving PEG-IFN / RBV x 48 weeks (n=225)
Berg et al., AASLD 2007 (179A)Berg et al., AASLD 2007 (179A)
Individualisation according to HCV genotype:
Shorter treatment in HCV-1?
Virologic response in patients with HCV-1 and HCV RNA < 600,000 IU/mL
0
10
20
30
40
50
60
70
80
90
All patients Week 4 Week 12 Week 24/EOT
SVR
Relapse
Time to first negative HCV RNAPEG-IFN -2b + RBVZeuzem et al., J Hepatol 2006
Pat
ient
s (%
)
(47%) (26%) (10%)
50%
37%
89%
25%17%
8%
75%80%
Early identification of HCV 1 patients responding to 24 wks PEG-IFN alfa-2a/RBV
89 88
73
91
1623
3544
0
20
40
60
80
100
HCV RNA < 50IU/mL at week 4
HCV RNA > 50IU/mL at week 4
24-LD
24-SD
48-LD
48-SD
Jensen et al., Jensen et al., HepatologyHepatology 2006;43:954-60
Sus
tain
ed v
irolo
gic
Sus
tain
ed v
irolo
gic
resp
onse
(%
)re
spon
se (
%)
18 33 40 55 81 84 208 210
Rates of relapse and SVR according to RVR and baseline viral load
3,60
96,4100
50,8
16,7
44,4
71,4
0102030405060708090
100
Relapse SVR Relapse SVR
24 wk tx
48 wk tx
Yu et al., Hepatology 2008; 47:1884-1893
LVL and RVRLVL and RVR HVL or non-RVRHVL or non-RVR
Res
pons
e (%
)R
espo
nse
(%)
Individualisation according to HCV genotype:
Longer treatment in HCV-1 ?
Extended treatment duration for HCV 1: 48 vs 72 weeks of PEG-IFN alfa-2a + RBV
80 76
17
29
0
10
20
30
40
50
60
70
80
HCV RNA < 50 IU/mL at week 12
HCV RNA ≥ 50 IU/mL at week 12
48 wks
72 wks
Sus
tain
ed v
irolo
gic
resp
onse
rat
e (%
)
Berg, et al. Gastroenterology 2006;130:1086-1097
104/130 90/119 17/100 31/106
P=0.040
Virologic relapse rates in patients with slow virologic response
37
23
64
40
0
10
20
30
40
50
60
70
> 50 IU/mL > 50 IU/mL
48 wks
72 wks
Berg, et al. Gastroenterology 2006;130:1086-1097
Viro
logi
c re
laps
e ra
te (
%)
Week 4 Week 12
30/47 21/5246/124 28/122
P=0.016 P=0.021
Peginterferon alfa-2a plus ribavirin for 48 vs. 72 weeks in patients with detectable
HCV RNA at week 4 of treatment
0
10
20
30
40
50
60
HCV-1 HCV-1 / <800,000 IU/mL
HCV-1 / >800,000 IU/mL
48 wks
72 wks
Sanchez-Tapias et al., Gastroenterology 2006;131:451-460
Sus
tain
ed v
irolo
gic
resp
onse
rat
e (%
)
28%
44%
27% 28%
51%
37%
P=0.003 P=0.002 P=0.35
Peginterferon alfa-2a plus ribavirin for 48 vs. 72 weeks in patients with detectable
HCV RNA at week 4 of treatment
0
10
20
30
40
50
60
HCV-1 HCV-1 / <800,000 IU/mL
HCV-1 / >800,000 IU/mL
48 wks
72 wks
Sanchez-Tapias et al., Gastroenterology 2006;131:451-460
Viro
logi
c re
laps
e ra
te (
%)
17%
53%
27%23%
55%50%
P=0.002 P=0.007 P=0.15
Viral kinetics: tailoring of therapyin HCV genotype 1 infected patients
HCV-1 (LVL, RVR) 24 weeksZeuzem et al. 2004; Zeuzem et al. 2005; Jensen et al. 2006
HCV-1 (cEVR) 48 weeksManns et al. 2002; Hadziyannis et al. 2004; Kamal et al. 2005
HCV-1 (SPR) 72 weeksButi et al. 2003; Berg et al. 2006; Sanchez-Tapias et al. 2006
Treatment of „Difficult-to-cure“ Patients
28%33%
36%32%
36%
47%
0%
10%
20%
30%
40%
50%
60%
70%
80%
NV15801 (Fried) NV15492(Hadziyannis)
NV17318
PEG-IFN alfa-2a 180 ug + RBV 1200 mg PEG-IFN alfa-2a 180 ug + RBV 1600 mgPEG-IFN alfa-2a 270 ug + RBV 1200 mg PEG-IFN alfa-2a 270 ug + RBV 1600 mg
Virologic Response in G1, HVL, > 85 kg patients
% P
ati
en
ts w
ith
VR
VR = HCV RNA < 50 copies/mL
Arm A (n=46)
Arm B, C,& D (n=47)
Fried et al., AASLD 2006
(n=66) (n=53)
SVR and anemia as functions of exposure AUC – HCV genotype 1
n = 242, Snoeck et al, Br J Clin Pharm 2006
Weight-based exposure of ribavirin and treatment response
46,4 48
22,5 25
7,1 5,9
48,4 50
72,167,7
86,782,1
0
10
20
30
40
50
60
70
80
90
24 wk tx 48 wk tx 24 wk tx 48 wk tx
<13.3 mg/kg/day
13.3-15.2 mg/kg/day
>15.2 mg/kg/day
Yu et al., Hepatology 2008; 47:1884-1893
Tre
atm
ent r
espo
nse
(%)
Tre
atm
ent r
espo
nse
(%)
RelapseRelapse SVRSVR
Case: HCV1, HVL, cirrhosis
5/06 Standard therapy
8/06 < 2 log decline (Hb 12.8)
9/06 High dose (270 µg PEG-IFN alfa-2a + 1600 mg RBV)
12/06 > 2 log decline (RBV 2000 mg)
3/07 HCV RNA negative
9/08 18 months therapy with HD + EPO
1/09 HCV RNA still negative (4 mo post-tx)
Conclusions
• Individualisation of treatment duration (24 – 72 weeks)
• Maintaining drug doses, subtle dose reductions when necessary
• Compliance and adherence very important• Successful treatment also possible in „difficult-to-
treat“ populations • Future options: small molecules (2011/12)
which influence treatment indications today